<DOC>
	<DOCNO>NCT01391715</DOCNO>
	<brief_summary>To best knowledge , randomize control trial compare double dose PPI therapy standard one dose PPI therapy NERD patient . Thus , hypothesize double dose PPI would accelerate sustain control symptom NERD patient .</brief_summary>
	<brief_title>Double-dose Rabeprazole Accelerates Sustains Control Symptoms Patients With NERD</brief_title>
	<detailed_description>In Asian , majority GERD case case nonerosive reflux esophagitis ( NERD ) . NERD difficult -to-treat acid reflux condition even PPI compare reflux esophagitis ( RE ) . In addition , quality life NERD patient quite low , NERD patient need quicker effective treatment option . At present , PPI-based step-down treatment recommend GERD patient . Doubling th PPI dose become commonly practice therapeutic strategy patient GERD fail PPI daily . In patient symptomatic GERD fail one dose PPI increase rate overall symptom improvement 22-26 % . There various mechanism standard dose PPI failure GERD patient . Esophageal hypersensitivity likely underlying mechanism significant number patient . Patients sensitive esophagus ( normal endoscopy pH test positive symptom index ) likely respond PPI twice day . It thus clinical interest determine whether increased dosage PPI achieve rapidly control symptoms patient NERD patient .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>heartburn and/or reflux least twice weekly absence visible esophageal mucosal break endoscopy pregnancy lactation Hx gastric surgery Hx gastric cancer peptic ulcer major medical problem ( include CHF , renal failure , COPD , asthma , liver cirrhosis ) severe systemic illness Hx malignancy , allergy Hx rabeprazole patient take antibiotic antisecretory agent include H2blocker PPI within 4 week endoscopy current usage steroid , NSAIDs , aspirin , anticoagulant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>Proton pump inhibitor</keyword>
	<keyword>standard dose</keyword>
	<keyword>Double dose</keyword>
</DOC>